[EBIO] Eleven Biotherapeutics, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 1.97 Change: 0.12 (6.49%)
Ext. hours: Change: 0 (0%)

chart EBIO

Refresh chart

Strongest Trends Summary For EBIO

EBIO is in the long-term down -81% below S&P in 8 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Eleven Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, is engaged in the discovery and development of protein therapeutics to treat eye diseases primarily in the United States. The company develops its therapeutics through AMP-Rx, a proprietary protein engineering platform. Its principal product candidate includes the EBI-005, a novel IL-1 receptor antagonist that is in Phase III clinical program for the treatment of moderate to severe dry eye diseases; and in Phase II clinical trial for the treatment of allergic conjunctivitis. The company?s preclinical product candidates comprise EBI-029, a novel inhibitor of the cytokine IL-6 for the treatment of retinal diseases, such as diabetic macular edema; and EBI-028, a novel inhibitor of the cytokine IL-17 for the treatment of uveitis, and other diseases of the back of the eye, such as dry age-related macular degeneration. Eleven Biotherapeutics, Inc. has a collaboration and license agreement with ThromboGenics N.V. to identify protein or peptide

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -67.94% Sales Growth - Q/Q-34.93% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-71.83% ROE-108.05% ROI-79.78%
Current Ratio9.94 Quick Ratio Long Term Debt/Equity0.22 Debt Ratio0.15
Gross Margin Operating Margin-1737.31% Net Profit Margin-1743.51% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities Cash From Investing Activities-30 K Cash From Operating Activities-8.48 M Gross Profit
Net Profit-6.52 M Operating Profit-7.6 M Total Assets46.58 M Total Current Assets46.14 M
Total Current Liabilities4.64 M Total Debt10 M Total Liabilities15.61 M Total Revenue240 K
Technical Data
High 52 week2.91 Low 52 week0.65 Last close2.91 Last change4.3%
RSI89.56 Average true range0.25 Beta0.91 Volume312.93 K
Simple moving average 20 days57.25% Simple moving average 50 days112.61% Simple moving average 200 days152.39%
Performance Data
Performance Week31.08% Performance Month179.81% Performance Quart179.81% Performance Half169.44%
Performance Year53.16% Performance Year-to-date258.82% Volatility daily6.79% Volatility weekly15.19%
Volatility monthly31.14% Volatility yearly107.86% Relative Volume103.31% Average Volume2.6 M
New High New Low

News

2018-06-19 10:00:00 | Biotech Company, ENDV Should Be On Everyone's Watchlist

2018-05-18 07:30:00 | Blog Exposure - ADMA Biologics Received US Patent for Treating Respiratory Infections

2018-05-17 08:00:00 | Today’s Research Reports on Stocks to Watch: Eleven Biotherapeutics and VIVUS

2018-05-16 06:30:00 | Eleven Biotherapeutics Announces Corporate Name Change to Sesen Bio

2018-05-15 16:05:00 | Eleven Biotherapeutics Reports First Quarter Financial Results and Pipeline Updates

2018-05-03 08:36:12 | Implied Volatility Surging for Eleven Biotherapeutics EBIO Stock Options

2018-05-03 08:20:00 | Today’s Research Reports on Stocks to Watch: Midatech Pharma and Eleven Biotherapeutics

2018-05-01 07:50:00 | Market Trends Toward New Normal in Emerge Energy Services LP, NACCO Industries, 8x8, Eleven Biotherapeutics, Monolithic Power, and Highwoods Properties — Emerging Consolidated Expectations, Analyst Ratings

2018-04-23 08:30:00 | Today's Research Reports on Trending Tickers: Eleven Biotherapeutics and CVS Health

2018-04-22 08:26:29 | Who Are The Largest Shareholders In Eleven Biotherapeutics Inc NASDAQ:EBIO?

2018-04-20 08:39:12 | Eleven Biotherapeutics EBIO in Focus: Stock Moves 8.7% Higher

2018-04-20 08:00:00 | With FDA Filing On The Horizon, NMTC Could Pull an EBIO-Like Move

2018-04-12 06:30:00 | New Preclinical Data Highlighting Eleven Biotherapeutics’ DeBouganin Program to be Presented at 2018 AACR Annual Meeting

2018-04-04 16:05:00 | Eleven Biotherapeutics Reports Fourth Quarter and Full-Year 2017 Operating Results and Vicinium Development Progress

2018-04-03 08:30:00 | Preliminary Data from Phase 3 VISTA Trial in Bladder Cancer to Be Presented in a Plenary Session at American Urological Association Annual Meeting

2018-03-21 09:20:00 | Eleven Biotherapeutics Announces Pricing of $10.0 Million Offering Priced At-the-Market

2018-03-20 12:52:27 | For Eleven Biotherapeutics, Cancer Trial Outcomes Could Be 'Major Catalyst'

2018-03-12 06:30:00 | Enrollment Completed in Phase 3 Registration Trial for Non-Muscle Invasive Bladder Cancer

2018-03-05 06:30:00 | Eleven Biotherapeutics to Present at the Cowen and Company 38th Annual Health Care Conference

2018-03-02 08:20:00 | New Research Coverage Highlights Eleven Biotherapeutics, Enova International, Veracyte, Ameris, Veritiv, and United Fire Group — Consolidated Revenues, Company Growth, and Expectations for 2018

2018-02-08 08:00:00 | Eleven Biotherapeutics to Present at 2018 BIO CEO & Investor Conference

2018-01-24 15:12:00 | Eleven Biotherapeutics Appoints Richard Fitzgerald as Chief Financial Officer

2018-01-08 07:40:00 | New Research Coverage Highlights ConnectOne, Rockwell Medical, Accelerate Diagnostics, Eleven Biotherapeutics, Renasant, and Natera — Consolidated Revenues, Company Growth, and Expectations for 2018

2018-01-02 16:30:00 | Eleven Biotherapeutics to Present at Biotech Showcase 2018

2017-12-13 07:00:00 | Eleven Biotherapeutics Announces Chief Scientific Officer to Chair a Session at the Antibody Engineering and Therapeutics Meeting

2017-12-01 07:20:00 | Wired News – Idera Pharma Gets Fast Track Designation for IMO-2125 in Combination with Ipilimumab for Treatment of PD-1 Refractory Metastatic Melanoma

2017-11-30 16:30:00 | Eleven Biotherapeutics to Present at the LD Micro Main Event 2017

2017-11-20 11:07:42 | Eleven Biotherapeutics, Inc.: Sudden move in price, will it continue?

2017-11-20 08:30:00 | Eleven Biotherapeutics Reports Third Quarter 2017 Financial Results

2017-11-20 08:00:00 | Today’s Research Reports on Stocks to Watch: Eleven Biotherapeutics and CytRx Corporation

2017-11-14 20:31:11 | Edited Transcript of EBIO earnings conference call or presentation 14-Nov-17 9:30pm GMT

2017-11-14 12:00:00 | Eleven Biotherapeutics, Inc. to Host Earnings Call

2017-11-09 16:30:00 | Eleven Biotherapeutics to Report Third Quarter 2017 Financial Results on November 14, 2017

2017-11-09 08:00:00 | Eleven Biotherapeutics to Present at Stifel 2017 Healthcare Conference

2017-11-03 16:31:00 | Eleven Biotherapeutics Announces Closing of $8.0 Million Underwritten Public Offering

2017-11-01 09:34:00 | Eleven Biotherapeutics Prices of $8.0 Million Underwritten Public Offering

2017-10-13 16:30:00 | Eleven Biotherapeutics Appoints Richard Fitzgerald as Interim Chief Financial Officer

2017-09-22 08:00:00 | Eleven Biotherapeutics Announces Completion of Vicinium Manufacturing for Ongoing Clinical Trials in Non-Muscle Invasive Bladder Cancer

2017-09-05 08:00:00 | Eleven Biotherapeutics to Present at the Rodman & Renshaw 19th Annual Global Investment Conference

2017-08-14 10:10:32 | Edited Transcript of EBIO earnings conference call or presentation 14-Aug-17 12:00pm GMT

2017-08-14 07:00:00 | Eleven Biotherapeutics Reports Second Quarter 2017 Financial Results

2017-08-14 06:00:00 | Investor Network: Eleven Biotherapeutics, Inc. to Host Earnings Call

2017-08-07 08:00:00 | Eleven Biotherapeutics to Report Second Quarter 2017 Financial Results on Monday, August 14, 2017

2017-08-03 16:05:00 | Eleven Biotherapeutics to Present at Canaccord Genuity 37th Annual Growth Conference

2017-07-13 15:52:48 | ETFs with exposure to Eleven Biotherapeutics, Inc. : July 13, 2017

2017-06-12 08:00:00 | Eleven Biotherapeutics to Present at 2017 Marcum MicroCap Conference

2017-06-06 08:00:00 | Eleven Biotherapeutics to Collaborate with AstraZeneca and the National Cancer Institute on Development of ViciniumTM in Combination with Durvalumab for the Treatment of Non-Muscle Invasive Bladder Cancer

2017-06-01 08:00:00 | Eleven Biotherapeutics Announces Data and Safety Monitoring Board DSMB Recommendation to Continue Phase 3 Registration Trial with Vicinium™ in Non-Muscle Invasive Bladder Cancer Based on Review of Safety and Efficacy Data

2017-05-26 13:05:55 | ETFs with exposure to Eleven Biotherapeutics, Inc. : May 26, 2017

2017-05-26 12:01:59 | Eleven Biotherapeutics, Inc.: Fading performance but may be making a comeback?